摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3b)-胆甾-5-烯-3-胺 | 2126-93-4

中文名称
(3b)-胆甾-5-烯-3-胺
中文别名
——
英文名称
cholest-5-en-3-amine
英文别名
cholest-5-en-3β-ylamine;3α-aminocholest-5-ene;3β-amino-5-cholestene;3β-aminocholest-5-en;3β-amino-cholestene;3β-cholesterylamine;Cholesterylamine;(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine
(3b)-胆甾-5-烯-3-胺化学式
CAS
2126-93-4
化学式
C27H47N
mdl
——
分子量
385.677
InChiKey
YGPZWPHDULZYFR-DPAQBDIFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    98 °C(Solv: methanol (67-56-1))
  • 沸点:
    470.8±24.0 °C(Predicted)
  • 密度:
    0.96±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    8.3
  • 重原子数:
    28
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.93
  • 拓扑面积:
    26
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 储存条件:
    -20°C,避光,惰性气体

SDS

SDS:94c56adafd509751f6b16e04a84027f1
查看

制备方法与用途

胆甾醇胺是一种阳离子脂质,可以将其加入PLGA中以制备带有表面电荷的PLGA颗粒。这种颗粒适用于药物递送,并且在自身免疫性疾病和过敏研究中也有应用价值。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    类固醇和瓦尔登反演。第二十二部分。胆固醇胺的构型
    摘要:
    DOI:
    10.1039/jr9550000690
  • 作为产物:
    描述:
    胆固醇 在 sodium azide 、 三苯基膦 作用下, 以 二氯甲烷N,N-二甲基甲酰胺 为溶剂, 反应 7.0h, 以85%的产率得到(3b)-胆甾-5-烯-3-胺
    参考文献:
    名称:
    一种将醇转化为胺的新型实用单锅法
    摘要:
    摘要 使用叠氮化钠、三苯基膦在 CC14-DMF 中将醇转化为胺,开发了一种方便有效的一锅法序列。
    DOI:
    10.1080/00397910008087402
点击查看最新优质反应信息

文献信息

  • DIARYLMETHYLAMIDE DERIVATIVE HAVING ANTAGONISTIC ACTIVITY ON MELANIN-CONCENTRATING HORMONE RECEPTOR
    申请人:Banyu Pharmaceutical Co., Ltd.
    公开号:EP2272841A1
    公开(公告)日:2011-01-12
    [Problem] To provide a melanin-concentrating hormone receptor antagonist useful as a pharmaceutical agent for central diseases, circulatory diseases, and metabolic diseases. [Means for Resolution] Provided is a diarylmethylamide derivative represented by formula (I): Wherein R1a, R1b, R2a, R2b, R3a, and R3b independently represent a hydrogen atom or the like, R4 represents a hydrogen atom, C1-6 alkyl, or the like, R5 represents a hydrogen atom or the like, Z represents C1-6 alkyl or the like, or R4 and Z together form a 4- to 6-membered nitrogen-containing hetero ring, Y1 represents H or the like, Y2 represents H, or Y1 and Y2 together form - O-CH2-, W represents C, SO, or the like, Ar1 represents 6-membered aryl or the like, Ar2 represents 6-membered aryl or the like, and ring A represents a benzene ring, a pyridine ring, or the like.
    [问题] 提供一种对黑色素浓缩激素受体拮抗剂,用作中枢疾病、循环疾病和代谢疾病的药用制剂。 [解决方法] 提供一种由式(I)表示的二芳基甲酰胺衍生物: 其中R1a、R1b、R2a、R2b、R3a和R3b独立地表示氢原子或类似物,R4表示氢原子、C1-6烷基或类似物,R5表示氢原子或类似物,Z表示C1-6烷基或类似物,或者R4和Z一起形成一个含氮杂环的4-至6-成员环,Y1表示H或类似物,Y2表示H,或者Y1和Y2一起形成-O-CH2-,W表示C、SO或类似物,Ar1表示6-成员芳基或类似物,Ar2表示6-成员芳基或类似物,环A表示苯环、吡啶环或类似物。
  • DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR
    申请人:Ando Makoto
    公开号:US20100324049A1
    公开(公告)日:2010-12-23
    [Problems] To provide an antagonist of a melanin-concentrating hormone receptor, which is useful as a medicine for a central nervous system disease, a cardiovascular disease or a metabolic disease. [Means for Solving Problems] The antagonist comprises, as an active ingredient, a compound represented by the formula (I) wherein R 1a and R 1b independently represent a hydrogen atom or a C 1-6 alkyl group; R 2a , R 2b , R 3a and R 3b independently represent a hydrogen atom, a C 1-6 alkyl group, or the like; Y represents H or —OH; Z represents —OR 8 , or the like; R 8 represents a hydrogen atom, a C 1-6 alkyl group which may have a substituent, or the like; R 9a and R 9b independently represent a hydrogen atom, a C 1-6 alkyl group, or the like; Ar 1 represents an aromatic carbon ring group, or an aromatic heteroring group; Ar 2 represents a group produced by removing two hydrogen atoms from an aromatic carbon ring, or the like; and the ring group A represents an unsaturated heteroring group.
    [问题] 提供一种黑素浓集激素受体的拮抗剂,该拮抗剂作为治疗中枢神经系统疾病、心血管疾病或代谢疾病的药物是有用的。 [解决问题的手段] 该拮抗剂包含作为活性成分的以下公式(I)所示的化合物: 其中 R1a 和 R1b 分别独立代表一个氢原子或一个C1-6烷基团;R2a、R2b、R3a 和 R3b 分别独立代表一个氢原子、一个C1-6烷基团或类似物;Y代表H或—OH;Z代表—OR8,或类似物;R8代表一个氢原子、一个可能含有取代基的C1-6烷基团或类似物;R9a和R9b分别独立代表一个氢原子、一个C1-6烷基团或类似物;Ar1代表一个芳香碳环族或芳香杂环族;Ar2代表通过从一个芳香碳环中移除两个氢原子而得到的族或类似物;而环族A代表一个不饱和杂环族。
  • Fluorescent mimics of cholesterol that rapidly bind surfaces of living mammalian cells
    作者:David Hymel、Sutang Cai、Qi Sun、Rebecca S. Henkhaus、Chamani Perera、Blake R. Peterson
    DOI:10.1039/c5cc06325f
    日期:——

    Novel analogues of cholesterol are rapidly and massively incorporated into the plasma membrane of living mammalian cells through a receptor-mediated pathway.

    新型类固醇类似物通过受体介导的途径迅速大量地被纳入活体哺乳动物细胞的质膜中。
  • [EN] DIARYLAMIDE-SPIRODIAMINE DERIVATIVE<br/>[FR] DÉRIVÉ DE DIARYLAMIDE-SPIRODIAMINE
    申请人:BANYU PHARMA CO LTD
    公开号:WO2010147234A1
    公开(公告)日:2010-12-23
    To provide a melanin concentrating hormone receptor antagonist useful as medicines for central system disorders, cardiovascular disorders and metabolic disorders. Provided is a compound of a formula (I): wherein R1a and R1b each are a hydrogen atom, etc.; R2 is a hydrogen atom, a C1-6 alkyl, etc.; Ar1 is a 6-membered aromatic carbocyclic group or a 6-membered aromatic nitrogen-containing heterocyclic group; Ar2 is a group to be formed by removing two hydrogen atoms from a 6-membered aromatic carbon ring, a 6-membered aromatic nitrogen-containing hetero ring, etc.; Ar3 is a mono- or bi-cyclic aromatic carbocyclic group or aromatic heterocyclic group; m1, m2, m3 and m4 are independently 0, 1, 2, 3 or 4, provided that the total of m1 and m2 is from 2 to 6, and the total of m3 and m4 is from 2 to 6. The compound is useful as medicines for central system disorders, cardiovascular disorders and metabolic disorders.
    提供一种黑色素浓缩激素受体拮抗剂,用作治疗中枢系统疾病、心血管疾病和代谢性疾病的药物。提供的化合物具有如下结构(I):其中R1a和R1b分别是氢原子等;R2是氢原子、C1-6烷基等;Ar1是6元芳香碳环基团或6元芳香氮杂环基团;Ar2是由6元芳香碳环中去除两个氢原子形成的基团,或者是6元芳香氮杂环等;Ar3是单环或双环芳香碳环基团或芳香杂环基团;m1、m2、m3和m4独立地为0、1、2、3或4,要求m1和m2的总和为2到6,m3和m4的总和为2到6。该化合物可用作治疗中枢系统疾病、心血管疾病和代谢性疾病的药物。
  • Novel compositions for the delivery of negatively charged molecules
    申请人:Ribozyme Pharmaceuticals, Inc.
    公开号:US20030073640A1
    公开(公告)日:2003-04-17
    This invention features permeability enhancer molecules, and methods, to increase membrane permeability of various molecules, such as nucleic acids, polynucleotides, oligonucleotides, enzymatic nucleic acid molecules, antisense nucleic acid molecules, 2-5A antisense chimeras, triplex forming oligonucleotides, decoy RNAs, dsRNAs, siRNAs, aptamers, or antisense nucleic acids containing nucleic acid cleaving chemical groups, peptides, polypeptides, proteins, carbohydrates, steroids, metals and small molecules, thereby facilitating cellular uptake of such molecules.
    本发明涉及一种透过性增强剂分子,及其方法,用于增加诸如核酸、多核酸、寡核酸、酶核酸分子、反义核酸分子、2-5A反义嵌合体、三链形成寡核酸、诱饵RNA、双链RNA、小干扰RNA、适配体或含有核酸切割化学基团的核酸、肽、多肽、蛋白质、碳水化合物、类固醇、金属和小分子等不同分子的膜透过性,从而促进细胞对这些分子的摄取。
查看更多